Applications

1403 – Lung Microwave Tissue Ablation

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Not supported

Application details

Reason for application

New MBS item.

Service or technology in this application

NON-RESECTABLE PRIMARY LUNG CANCER AND PULMONARY METASTATIC DISEASE, destruction of, by percutaneous microwave tissue ablation (MTA), including any associated imaging services. Under multidisciplinary assessment, MTA is conducted in the following circumstances: Surgical resection is not possible due to the presence of lesions in unresectable locations, the number and anatomical distribution, poor cardiopulmonary function and/or other comobidities. Stereotactic body radiation therapy (SBRT) is not available or contraindicated. In conjunction with lung resection, chemotherapy, radiotherapy or other cancer treatments.

Type: Therapeutic

Medical condition this application addresses

MTA is primarily targeted at the 15% of all patients and 30% of patients aged over 75 years with early stage NSCLC who are not candidates for surgical resection (Dupuy 2013). This ablation modality may also be used in patients with pulmonary metastases, where number and site of metastases, or previous lung surgery, precludes them from (further) surgery (Hiraki 2012).

Meetings to consider this application

  • PASC meeting: 13 August 2015
  • ESC meeting: 6 - 7 October
  • MSAC meeting: 24 - 25 November 2016